"J\u00E1nsk\u00FD, Petr" . . "Dlouhodob\u00E1 zku\u0161enost s dabigatranem v antikoagula\u010Dn\u00ED l\u00E9\u010Db\u011B fibrilace s\u00EDn\u00ED. Studie RELY-ABLE" . . . . "RELY-ABLE study; atrial fibrilation"@en . . "1"^^ . . "I" . "70099" . . "1"^^ . "Patients in the RE-LY randomized to treatment with dabigatran, to participate in long-term follow-up study RELY-ABLE. It enrolled the 5851 patients who were followed for an average of 2.3 years. The incidence of stroke or systemic embolism and major bleeding incidence remained low and was consistent with the study RE-LY. At a dose of 150 mg twice daily of dabigatran was slightly higher incidence of major bleeding as compared with a dose of 110 mg twice daily. The incidence of thromboembolic events and mortality were similar for both doses of dabigatran."@en . "RIV/00064203:_____/13:10196091" . . . "3"^^ . "Pacienti, kte\u0159\u00ED byli ve studii RE-LY randomizov\u00E1ni k l\u00E9\u010Db\u011B dabigatranem, se mohli z\u00FA\u010Dastnit dlouhodob\u00E9ho sledov\u00E1n\u00ED v navazuj\u00EDc\u00ED studii RELY-ABLE. Bylo do n\u00ED za\u0159azeno 5851 pacient\u016F, kte\u0159\u00ED byli sledov\u00E1ni pr\u016Fm\u011Brn\u011B 2,3 roku. V\u00FDskyt c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod nebo syst\u00E9mov\u00FDch embolizac\u00ED a v\u00FDskyt z\u00E1va\u017En\u00FDch krv\u00E1cen\u00ED z\u016Fstal n\u00EDzk\u00FD a byl konzistentn\u00ED se studi\u00ED RE-LY. P\u0159i d\u00E1vce 150 mg dabigatranu dvakr\u00E1t denn\u011B byl lehce vy\u0161\u0161\u00ED v\u00FDskyt z\u00E1va\u017En\u00FDch krv\u00E1cen\u00ED ve srovn\u00E1n\u00ED s d\u00E1vkou 110 mg pod\u00E1vanou dvakr\u00E1t denn\u011B. Incidence tromboembolick\u00FDch p\u0159\u00EDhod a mortalita byly podobn\u00E9 u obou d\u00E1vek dabigatranu."@cs . "23" . "Long-term experience with dabigatran anticoagulation therapy in atrial fibrilation. RELY-ABLE study"@en . "Dlouhodob\u00E1 zku\u0161enost s dabigatranem v antikoagula\u010Dn\u00ED l\u00E9\u010Db\u011B fibrilace s\u00EDn\u00ED. Studie RELY-ABLE"@cs . "Pacienti, kte\u0159\u00ED byli ve studii RE-LY randomizov\u00E1ni k l\u00E9\u010Db\u011B dabigatranem, se mohli z\u00FA\u010Dastnit dlouhodob\u00E9ho sledov\u00E1n\u00ED v navazuj\u00EDc\u00ED studii RELY-ABLE. Bylo do n\u00ED za\u0159azeno 5851 pacient\u016F, kte\u0159\u00ED byli sledov\u00E1ni pr\u016Fm\u011Brn\u011B 2,3 roku. V\u00FDskyt c\u00E9vn\u00EDch mozkov\u00FDch p\u0159\u00EDhod nebo syst\u00E9mov\u00FDch embolizac\u00ED a v\u00FDskyt z\u00E1va\u017En\u00FDch krv\u00E1cen\u00ED z\u016Fstal n\u00EDzk\u00FD a byl konzistentn\u00ED se studi\u00ED RE-LY. P\u0159i d\u00E1vce 150 mg dabigatranu dvakr\u00E1t denn\u011B byl lehce vy\u0161\u0161\u00ED v\u00FDskyt z\u00E1va\u017En\u00FDch krv\u00E1cen\u00ED ve srovn\u00E1n\u00ED s d\u00E1vkou 110 mg pod\u00E1vanou dvakr\u00E1t denn\u011B. Incidence tromboembolick\u00FDch p\u0159\u00EDhod a mortalita byly podobn\u00E9 u obou d\u00E1vek dabigatranu." . "CZ - \u010Cesk\u00E1 republika" . "RIV/00064203:_____/13:10196091!RIV14-MZ0-00064203" . "Dlouhodob\u00E1 zku\u0161enost s dabigatranem v antikoagula\u010Dn\u00ED l\u00E9\u010Db\u011B fibrilace s\u00EDn\u00ED. Studie RELY-ABLE" . "[5FA7F4CB6F75]" . . "Long-term experience with dabigatran anticoagulation therapy in atrial fibrilation. RELY-ABLE study"@en . "Remedia" . "Dlouhodob\u00E1 zku\u0161enost s dabigatranem v antikoagula\u010Dn\u00ED l\u00E9\u010Db\u011B fibrilace s\u00EDn\u00ED. Studie RELY-ABLE"@cs . . . . "0862-8947" . "5" . .